| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Medical and professional news |
| Population | Men |
| Source | Medical Dialogues |
| URL | medicaldialogues.in/amp/nephrology/news/testosterone-replacement-therapy-appears-safe-and-improves-survival-in-ckd-with-hypogonadism-study-168474 (opens in a new tab) |
Specific Claim Evaluated
Testosterone replacement therapy improves survival in men with chronic kidney disease and hypogonadism.
Primary Research Supporting or Contradicting the Claim
A retrospective propensity-matched cohort of 3,090 men with CKD stages 3 to 5 found that testosterone therapy was associated with lower all-cause mortality (hazard ratio 0.78), with no significant differences in cardiovascular events, prostate cancer or dementia (Merlino et al., 2026).
Corrected Evidence-Based Interpretation
In an observational database study, testosterone use was associated with lower mortality in men with CKD and hypogonadism. Residual confounding, including healthier patients being selected for treatment, cannot be excluded, and randomized trials are needed.
Rationale for Grade
The body uses associational language and calls for randomized trials, but the headline states that therapy improves survival, which is a causal claim the design cannot support. The article also presents nonsignificant differences as evidence of safety.
References
- Merlino L, Rainone F, Tollitt J, Kalra MJ, Williford S, Rusconi F, Battini GG, Dunne RA, Hackett G, Kalra PA. Safety of testosterone therapy in chronic kidney disease: a propensity score-matched cohort study. World J Mens Health. 2026;44:e24. PMID
Supporting excerpt: "TRT was associated with improved survival"